Browse Technologies

Displaying 1 - 3 of 3


Small Molecule mGlu3 NAMs as Therapeutics for CNS Disorders

The Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) has a mission to promote the translation of advances in basic science towards novel therapeutics. They have recruited faculty and staff with experience at over 10 different pharmaceutical companies to ensure a diverse set of approaches, techniques and philosophies to advancing compounds. Together they aim to de-risk drug discovery programs.


Licensing Contact

Mike Villalobos

615.322.6751
Therapeutics
Small Molecule

mGlu3 NAMs as Therapeutics for Chemoresistant Tumors

Targeting metabotropic glutamate receptor 3 (mGlu3) has been linked as a potential therapeutic to many neurological disorders and well as oncology through the use of dual specific mGlu2/3 Antagonists (LY341495, RO4491533, MGS0039, RO4988546).


Licensing Contact

Mike Villalobos

615.322.6751
Therapeutics
Small Molecule

An Ergothioneine PET Radioligand for Imaging Oxidative Stress in Alzheimer's Disease

Vanderbilt researchers lead by Professor Wellington Pham, PhD, have developed a novel ergothioneine (ERGO) PET radioligand for imaging oxidative stress in Alzheimer's disease.


Licensing Contact

Masood Machingal

615.343.3548
Therapeutics
Neuroscience/Neurology